Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

June 29, 2026 7:09 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $22.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles